- Home
- OXBR vs NCNA Comparison
OXBR vs NCNA Comparison
Compare OXBR & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OXBR | NCNA |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | Cayman Islands | United Kingdom |
| Employees | 3 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 8.8M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | OXBR | NCNA |
|---|---|---|
| Price | $0.94 | $1.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 8.8K | ★ 32.8K |
| Earning Date | 04-06-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $497.99 | N/A |
| Revenue Next Year | $42.14 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $0.03 |
| 52 Week High | $2.85 | $10.00 |
Technical Indicators
Market Signals| Indicator | OXBR | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 43.02 | 26.66 |
| Support Level | $0.76 | $0.05 |
| Resistance Level | $1.46 | $2.27 |
| Average True Range (ATR) | 0.06 | 0.16 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 53.57 | 1.69 |
Price Performance
Historical ComparisonAbout OXBR Oxbridge Re Holdings Limited
Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.